Correlation Between Hanesbrands and Cidara Therapeutics

Can any of the company-specific risk be diversified away by investing in both Hanesbrands and Cidara Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hanesbrands and Cidara Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Hanesbrands and Cidara Therapeutics, you can compare the effects of market volatilities on Hanesbrands and Cidara Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hanesbrands with a short position of Cidara Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hanesbrands and Cidara Therapeutics.

Diversification Opportunities for Hanesbrands and Cidara Therapeutics

-0.12

Correlation Coefficient

Hanesbrands  Cidara Therapeutics

Good diversification

The 3 months correlation between Hanesbrands and Cidara is -0.12. Overlapping area represents the amount of risk that can be diversified away by holding Hanesbrands and Cidara Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cidara Therapeutics and Hanesbrands is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hanesbrands are associated (or correlated) with Cidara Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cidara Therapeutics has no effect on the direction of Hanesbrands i.e., Hanesbrands and Cidara Therapeutics go up and down completely randomly.

Pair Corralation between Hanesbrands and Cidara Therapeutics

Considering the 90-day investment horizon Hanesbrands is expected to under-perform the Cidara Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Hanesbrands is 1.41 times less risky than Cidara Therapeutics. The stock trades about -0.16 of its potential returns per unit of risk. The Cidara Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  2,525  in Cidara Therapeutics on December 30, 2024 and sell it today you would lose (286.00) from holding Cidara Therapeutics or give up 11.33% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Hanesbrands  vs.  Cidara Therapeutics

Hanesbrands

Risk-Adjusted Performance

Very Weak

Over the last 90 days Hanesbrands has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's fundamental drivers remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Cidara Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cidara Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Cidara Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Hanesbrands and Cidara Therapeutics

The main advantage of trading using opposite Hanesbrands and Cidara Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hanesbrands position performs unexpectedly, Cidara Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cidara Therapeutics will offset losses from the drop in Cidara Therapeutics' long position.

The idea behind Hanesbrands and Cidara Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.